U.S. Group Challenges Gilead’s Hepatitis C Drug Patents In 5 Countries

Reuters: Gilead patents on costly hepatitis C drug challenged in five countries
“A U.S. group is trying to block patents in five countries for Gilead Sciences Inc.’s costly hepatitis C drug Sovaldi, in a bid to give almost 60 million afflicted people access to cheaper generic versions. In Argentina, Brazil, China, Russia, and Ukraine, challenges have been filed against Gilead’s patents or patent applications, the New York-based Initiative for Medicines, Access & Knowledge, or I-MAK, said on Wednesday…” (Pierson, 5/20).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.